Photography exhibit features breast and ovarian cancer patients and families

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Data show deep responses with rinatabart sesutecan among patients regardless of folate receptor alpha expression level in a phase 1/2 study.

The adverse effect profile of abemaciclib plus hormonal therapy was comparable with prior reports of CDK4/6 inhibitors.